中医药靶向肉瘤病毒癌基因相关疾病。
Traditional Chinese Medicine Targeting Sarcoma Virus Oncogene-related Diseases.
机构信息
Experiment Center for Science and Technology, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
出版信息
Curr Cancer Drug Targets. 2023;23(10):751-763. doi: 10.2174/1568009623666230426093244.
The sarcoma virus oncogene (Src) tyrosine kinase, a nonreceptor protein-tyrosine kinase, plays a crucial role in cell survival, migration, differentiation and proliferation. The study of Src has developed considerably since it was first discovered as a proto-oncogene. Src has also been associated with inflammation and bone-related diseases. Src inhibitors (bosutinib, ponatinib, dasatinib, and vandetanib) have been put into clinical use. However, their side effects and cardiovascular toxicity may be a concern. There is an urgent need to explore new Src inhibitors. Traditional Chinese medicine (TCM), which has a vast history, can provide a broad resource base. Many natural compounds and TCM extracts have the potential for anti-Src treatment. This article describes the natural compounds and extracts from TCM.
肉瘤病毒致癌基因（Src）酪氨酸激酶是一种非受体蛋白酪氨酸激酶，在细胞存活、迁移、分化和增殖中起着关键作用。自首次发现作为原癌基因以来，Src 的研究已经有了很大的发展。Src 也与炎症和骨骼相关疾病有关。Src 抑制剂（博舒替尼、帕纳替尼、达沙替尼和凡德他尼）已投入临床使用。然而，它们的副作用和心血管毒性可能是一个问题。迫切需要探索新的 Src 抑制剂。拥有悠久历史的中药（TCM）可以提供广泛的资源基础。许多天然化合物和中药提取物具有抗 Src 治疗的潜力。本文描述了来自 TCM 的天然化合物和提取物。
Zotero 插件